KarXT Eases Hallucinations in Alzheimer's Patients
Preliminary Phase 3 data from Bristol Myers Squibb show improved hallucination and delusion scores in Alzheimer's patients.
Updated on Nov. 18, 2026 in Alzheimer’s

Live Poll
Would you trust a new drug to help a loved one's Alzheimer's symptoms?
Bristol Myers Squibb reported that its KarXT treatment improved scores of hallucinations and delusions in Alzheimer's patients in a Phase 3 study, with overall disease severity scores also improving. A separate safety-focused study found the treatment was generally well tolerated through week 52.
Why it matters
Alzheimer's disease is the most common type of dementia in adults, and about 30% to 50% of patients experience hallucinations and delusions, known as psychosis, over the course of the disease. Results addressing these symptoms could matter for patients and caregivers facing this specific challenge.
The results come from preliminary Phase 3 data, with 65% of participants experiencing treatment-emergent adverse events and 7.7% experiencing serious ones through week 52. Full study results have not yet been released, and the comparison against a control group is not reported.
The players
Bristol Myers Squibb
Bristol Myers Squibb is a multinational pharmaceutical company headquartered in New York that develops treatments across oncology, immunology and neuroscience.
The details
Bristol Myers Squibb's KarXT treatment showed improvements in scores measuring hallucinations and delusions, as well as overall disease severity, in Alzheimer's patients in preliminary Phase 3 data. A separate safety-focused study found the treatment was generally well tolerated through week 52, with low rates of discontinuation.
Timeline
Bristol Myers Squibb announced the preliminary Phase 3 results on November 18, 2026.
The safety-focused study followed participants through week 52.
Health Landscape
Treating psychosis in Alzheimer's disease has long relied on antipsychotic drugs that carry safety warnings for older dementia patients. KarXT's preliminary results add a new candidate to that treatment landscape, though its full Phase 3 findings remain pending.
For Alzheimer's patients experiencing hallucinations or delusions, a treatment that improves these symptoms could change daily care options if approved. Patients and caregivers should discuss any emerging treatment with a physician, since full study results are not yet available.
The takeaway
Hallucinations and delusions affect a large share of Alzheimer's patients, so progress on treating them matters for families. Full Phase 3 results will show whether the early improvements hold up.
Further reading
For more on the disease at the center of this research, see the Alzheimer's section.
Source note: This article includes information reported by Morningstar.
Live Poll
Would you trust a new drug to help a loved one's Alzheimer's symptoms?







